This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre Hospitalier Regional Universitaire De Brest, Centre National De La Recherche Scientifique, Institut Curie. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 5,383 
1 out of 163 
Years Active: 2022
Title: Robin Fahraeus and His Patent on EBV-Related Cancers
Introduction
Robin Fahraeus is an inventor associated with research in Paris, France. His work includes a patent describing compounds intended to prevent or treat cancers associated with the Epstein-Barr virus (EBV).
Latest Patents
The available information lists 1 patent for Robin Fahraeus: “Hydrazone Derivatives for Preventing or Treating EBV-Related Cancers.” The invention concerns bis-hydrazone derivatives, along with compositions and kits containing them. The patent describes these derivatives as potential drugs for preventing or treating cancers associated with EBV.
Career Highlights
Fahraeus is associated with the Centre National de la Recherche Scientifique and Institut Curie. The patent reflects research into chemical compounds with potential applications in cancer prevention and treatment.
Collaborations
The listed coworkers include Claire Beauvineau and Alicia Quillevere. Their names are provided as collaborators associated with Fahraeus’s work.
Conclusion
Robin Fahraeus’s patent focuses on bis-hydrazone derivatives and their potential use against EBV-related cancers, connecting his research to institutions including the Centre National de la Recherche Scientifique and Institut Curie.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile